Cemiplimab likewise improved survival in EMPOWER-Lung 1 for PD-L1 ≥ 50% NSCLC, with durable benefit in longer follow-up analyses [96,97] (Table 3). Here, CD274 is linked to non-small cell lung carcinoma.